Learning outcomes
By the end of this lesson you should be able to: describe B-cell development and the receptor-rearrangement that creates antibody diversity; distinguish T-dependent from T-independent antigens and explain which vaccine types follow which route; describe B-cell activation, the germinal-centre reaction, somatic hypermutation and affinity maturation; describe the five classes of immunoglobulin with their structure, distribution and dominant function; explain the primary and secondary antibody responses and how serology reports them; and interpret a serology report in a specific clinical scenario, including the window period.
Prerequisites
Lesson 5 — Innate immunity. You need complement, opsonisation and the dendritic cell that presents antigen to the T cell which in turn helps the B cell.
The big idea
Each B cell carries one antibody of one specificity on its surface, and the population as a whole carries millions of specificities. Activation of a clone expands it enormously, so a tiny precursor frequency becomes a large effector response — and the same machinery produces memory cells, whose expanded clone gives the second response its speed and its volume.
The defining property of humoral immunity is that it acts on the extracellular world. It cannot see an organism once it is inside a cell, which is why intracellular pathogens — mycobacteria, Salmonella, chlamydiae, viruses — are controlled by cell-mediated immunity and stalled by antibodies. Where a patient has lost all antibody production, they get encapsulated pus-forming bacteria; where they have lost T cells, they get intracellular organisms and viruses.
B-cell development
B cells are made in the bone marrow. In the pro-B-cell stage, the immunoglobulin heavy-chain gene is assembled by somatic recombination: RAG-1 and RAG-2 cut and rejoin a D segment to a J segment and then to a V segment. In the pre-B-cell stage the light-chain locus undergoes the same recombination, and a functional light chain pairs with the mu heavy chain to make surface IgM. Because each recombination is imprecise, and because terminal deoxynucleotidyl transferase inserts random nucleotides at the junctions, the joining itself creates diversity before any antigen is met.
| Stage | What is happening | Checkpoint |
|---|---|---|
| Pro-B | Heavy-chain D to J, then V to DJ recombination | Whether a heavy chain can be made at all |
| Pre-B | Light-chain V to J recombination; heavy chain pairs with surrogate light chain | Whether the mu chain and the surrogate make a signalling-competent pre-B receptor |
| Immature B | Full surface IgM is expressed and one light chain is in place | Negative selection in the bone marrow — a strongly self-reactive receptor is deleted |
| Transitional B in spleen | Co-expression of IgD begins alongside IgM | Escape from central tolerance |
| Mature naive B | Surface IgM and IgD; recirculating between blood and lymphoid follicles | Ready to meet antigen |
NoteOne in every three B cells in a healthy adult is autoreactive at the time it leaves the marrow, and peripheral mechanisms — receptor editing, anergy, and regulatory T-cell suppression — eliminate or neutralise the rest. The failure of those peripheral mechanisms, not the bone marrow, is where most autoimmune disease begins.
Antigen types: why this matters for vaccines
| Antigen class | Examples | Response without T help? | Ig classes made | Vaccine significance |
|---|---|---|---|---|
| T-dependent | Proteins, peptides, glycoproteins, toxoids | No — needs a T follicular helper cell | IgM, then class-switched IgG, IgA or IgE; affinity maturation and memory | The strongest, most durable vaccines — toxoid, subunit and mRNA vaccines |
| T-independent type 1 | Lipopolysaccharide, other mitogenic structures | Yes, at high dose | Mostly IgM, weak class switch | Poor vaccine antigens; used as adjuvants and carriers |
| T-independent type 2 | Repeating polysaccharides, capsular polymers | Yes — cross-link the B-cell receptor directly | IgM, limited switched memory | Plain polysaccharide vaccines are poorly immunogenic below age two and give short-lived immunity |
NoteThe conjugate vaccines are the answer to the T-independent problem. By linking the capsular polysaccharide of Haemophilus influenzae type b, Streptococcus pneumoniae or Neisseria meningitidis to a carrier protein, the vaccine converts a T-independent response into a T-dependent one: T cells that recognise the protein provide help, so the B cell makes IgG, undergoes affinity maturation and produces memory. This is why Hib conjugate works in infants when plain polysaccharide did not, and it is the most important design lesson in vaccine immunology.
B-cell activation and the germinal centre
Activation requires two signals. The first is antigen cross-linking the B-cell receptor — the surface immunoglobulin — which delivers a primary signal through Ig-alpha and Ig-beta. The second comes from the T follicular helper cell: CD40 ligand engages CD40 on the B cell and interleukins 4, 21 and 10 direct class switching. A second, early pathway activates the B cell through TLRs receiving microbial PAMP, which is how an innate signal answers the question of whether the antigen is also dangerous.
After activation, the clone B cells enter a primary follicle and form a germinal centre. In the dark zone the cells proliferate rapidly and their variable-region genes are mutated by activation-induced cytidine deaminase, at roughly one mutation per cell per division — a thousand times the normal somatic mutation rate. In the light zone, selection decides which mutations survive: follicular dendritic cells display intact antigen on their processes, and only a cell whose mutated receptor binds that antigen more avidly is permitted to recapture it and present peptide to the T helper cell.
NoteGerminal centres are measurable at work. After vaccination, a lymph node enlarges and high-endothelial venules permit the entry that the response needs; the somatic hypermutation rate is so high that the response can be followed by sequencing the variable genes of individual responding B cells — and those sequences are the basis of research into next-generation vaccines.
The immunoglobulins
| Class | Structure | Concentration in serum | Distribution and half-life | Dominant functions |
|---|---|---|---|---|
| IgM | Pentamer of five basic units, with a J chain; largest antibody at 900 kDa | About 0.5–2 g/L | Confined to intravascular space because of its size; half-life about 5 days | The first antibody made; the most efficient complement activator; the anti-blood-group and anti-bacterial antibodies; IgM cannot cross the placenta |
| IgG | Monomer, 150 kDa; four subclasses IgG1, IgG2, IgG3, IgG4 | About 8–16 g/L, roughly 75 per cent of serum immunoglobulin | Distributed intra- and extra-vascularly; half-life about 23 days | The workhorse: neutralisation, opsonisation, complement activation (IgG1 and IgG3 best), and the only class that crosses the placenta |
| IgA | Monomer in serum, dimer with a secretory component at mucosal surfaces; half-life about 6 days | About 2–3 g/L in serum, and the dominant class on mucosal surfaces | Secretory IgA is produced by lamina propria plasma cells and transported across epithelium by the polymeric immunoglobulin receptor | Mucosal immunity: neutralises viruses and bacteria at the gut, respiratory and genitourinary surfaces before they cross |
| IgD | Monomer; serum concentration very low and half-life about 3 days | Mainly as surface IgD on naive B cells | Functions as a B-cell receptor and a component of regulatory signalling | |
| IgE | Monomer, 190 kDa; the lowest serum concentration of the classes | Bound to mast cells and basophils through the high-affinity Fc epsilon receptor I | Type I hypersensitivity and defence against helminths — mast cell degranulation releases histamine and eosinophil-recruiting factors |
NoteTwo facts about IgA are worth memorising. First, secretory IgA is made as a dimer and carried across the epithelium by the poly-Ig receptor, which leaves the secretory component still attached after cleavage — that is why gut IgA contains the protective component that resists proteolysis. Second, breast milk is rich in secretory IgA, and the first colostrum is the single most important passive protection a newborn receives for the first weeks of life.
Class switching changes the constant region, not the specificity
Each antibody class has the same variable region once a clone has been selected — the same antigen-binding site — and differs only in its constant region, which determines its tissue distribution and its effector functions. Switching is mediated by switch recombination upstream of the constant-region genes, directed by cytokines: interleukin-4 and interleukin-13 drive IgE and IgG4 switching, interferon-gamma drives IgG1 and IgG3, and transforming growth factor-beta and interleukin-5 drive IgA in the gut.
| Cytokine | Switches toward | Immunological context |
|---|---|---|
| Interleukin-4 (and interleukin-13) | IgE and IgG4 | A Th2-dominated response — helminths, allergy, asthma |
| Interferon-gamma | IgG1 and IgG3 (in humans), which fix complement well | A Th1-dominated response to intracellular organisms |
| Transforming growth factor-beta, interleukin-5, interleukin-10 | IgA | Mucosal immune response in gut and respiratory lamina propria |
Primary and secondary responses, and what serology means
| Feature | Primary response | Secondary response |
|---|---|---|
| Lag after exposure | About 3–5 days before antibody is detectable | About 1–2 days |
| Class made first | IgM, then IgG after class switching | IgG immediately, with only a brief IgM tail |
| Peak titre | Low and short-lived | High and sustained for months to years |
| Affinity | Low, improving through maturation | High — the memory cell has already matured |
| Cells responsible | Naive B cells | Memory B cells, already expanded and switched |
This is why serology reports carry a class label. IgM suggests recent infection — but with an important caveat, because IgM persists for weeks to months, is made again on re-exposure, and gives false positives with rheumatoid factor and Epstein–Barr virus. A single IgG titre is only evidence of past exposure. The strongest serological argument for recent infection is a pair: a fourfold or greater rise in IgG titre between an acute and a convalescent sample, two to three weeks apart.
Watch outThe window period defeats single-sample serology. In HIV, viral RNA is detectable within about ten days and p24 antigen within about two weeks, but antibody may not be detectable for three to twelve weeks — so an early negative HIV test in a patient with a clear exposure must be repeated, and a fourth-generation combination test, or a nucleic acid test, is the answer.
A pregnant woman has rubella IgG positive at 320 IU/mL and IgM negative. The report is evidence of past vaccination or past infection, not of current infection. Her immunity protects the fetus, so no action is needed. Were her IgM positive and IgG borderline, the correct response is a repeat sample two weeks later and comparison of titres, plus specialist advice — because rubella in early pregnancy threatens the fetus.
Therapeutic antibodies
The same machinery that natural specificity provides is the basis of monoclonal antibody therapy. A mouse antibody is humanised to reduce immunogenicity, retaining only the complementary-determining regions that bind antigen. Rituximab removes CD20-positive B cells and depletes humoral immunity, which is why pre-treatment hepatitis B screening is mandatory before it is given; infliximab neutralises tumour necrosis factor; and bevacizumab binds vascular endothelial growth factor. These drugs are humoral immunity applied deliberately — and their complication is precisely the loss of antibody function that depletes humoral immunity.
Common mistakes
Watch outSaying IgG means 'old infection' and IgM means 'new infection'. IgM persists for some months and may be re-elicited on re-exposure; IgG appears early in a strong secondary response. The stronger statement is that IgM in a single sample suggests recent infection, and IgG requires a fourfold rise or a documented seroconversion.
Watch outThinking class switching changes what the antibody binds. It changes the constant region — the effector tail — and therefore the tissue distribution and the complement-fixing ability, but the variable region, and therefore the antigen-binding site, is unchanged.
Watch outConfusing humoral with cellular immunity by disease. Antibody deficiency gives repeated sinopulmonary infection with encapsulated organisms: the killed-virus vaccine immunogenicity is lost, and live vaccines of any kind can be given because cell-mediated immunity is intact. T-cell deficiency gives opportunistic intracellular infection: Pneumocystis, chronic cryptosporidiosis, disseminated BCG after live vaccination — and live vaccines are dangerous.
Check your understanding
Why do plain polysaccharide vaccines fail in children under two years of age, and how does a conjugate vaccine solve the problem?
A laboratory reports a single sample positive for rubella IgG and negative for rubella IgM in a woman at 10 weeks of pregnancy. What does it mean and what action follows?
Why does a second dose of a protein vaccine give a higher and faster antibody response than the first?
Multiple choice
Which statement about IgG and IgM is correct?
A vaccine containing only purified bacterial capsular polysaccharide gives weaker and shorter-lived immunity than expected. What is the mechanism, and what is the remedy?
Which immunoglobulin is found in highest concentration in mucosal secretions?
Summary and next
Humoral adaptive immunity is antibody. B-cell receptors are generated by RAG-mediated V(D)J recombination, and each clone is selected by antigen, expanded in germinal centres, hypermutated and affinity-matured, with class switching directed by cytokines to produce IgM, the subclasses of IgG, IgA or IgE — the same variable region throughout. Antibody works by neutralisation, opsonisation and complement activation; secretory IgA guards the mucosa; maternal IgG protects the fetus and the neonate; and serology works on the asymmetric timing of primary and secondary responses, with a fourfold IgG rise or a documented seroconversion as the strongest evidence of infection.
Next: cell-mediated adaptive immunity. The half of the story that antibody cannot reach: antigen presentation, T-cell subsets, cytotoxic killing, and the delayed-type hypersensitivity that makes the tuberculin reaction read a week later rather than an hour later.